Hans J. Moebius

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Serge Gauthier, Howard Feldman, Lon S. Schneider et al. · The Lancet · 2016 · 405 citations · Full text

Neurodegenerative Diseases, Alzheimer's Disease, Pharmacology +10

Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group

Philippe Robert, Krista L. Lanctôt, Luis Agüera-Ortíz et al. · European Psychiatry · 2018 · 297 citations · Full text

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Gordon Wilcock, Serge Gauthier, Giovanni B. Frisoni et al. · Journal of Alzheimer s Disease · 2017 · 210 citations · Full text

Diagnostic criteria for apathy in neurocognitive disorders

David S. Miller, Philippe Robert, Larry Ereshefsky et al. · Alzheimer s & Dementia · 2021 · 157 citations · Full text

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

Richard S.E. Keefe, Herbert Meltzer, Nancy Dgetluck et al. · Neuropsychopharmacology · 2015 · 144 citations · Full text